https://www.raphaelcapital.com/news daily 0.75 2021-03-16 https://www.raphaelcapital.com/news/2021/3/16/fda-grants-breakthrough-device-designation-for-podascan-chronic-wound-diagnostic monthly 0.5 2021-03-16 https://www.raphaelcapital.com/news/2018/9/13/supernus-to-acquire-biscayne-neurotherapeutics monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2018/1/10/significant-supplements-launched-its-first-product-utilizing-yale-university-technology monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2017/12/12/significant-supplements-licenses-acid-reflux-technology-from-yale-university monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2017/12/11/emunamedica-awarded-category-iii-reimbursement-coding-by-cpt-ama-committee monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2016/10/13/partikula-appoints-leading-cancer-metabolism-experts-to-advisory-board-extends-its-work-on-its-multiple-checkpoint-inhibitors-adds-seasoned-technical-development-professional-to-the-m-gfmek monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2015/12/4/partikula-reports-positive-results-from-a-multi-checkpoint-protein-inhibition-study-of-its-first-in-class-precision-tumor-microenvironment-modifiers-tmem monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2015/10/5/insero-health-adding-clinical-stage-novel-epilepsy-program-and-other-cns-assets monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2015/2/2/partikula-announces-5-million-series-a-funding-to-develop-novel-first-in-class-mitochondrial-targeted-therapeutics monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2019/5/7/chronic-wound-diagnostics-company-emunamedica-announces-receipt-of-us-patent-allowance monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2013/5/17/insero-health-reports-positive-data-on-phase-i-trial-of-novel-therapy-for-drug-resistant-epilepsy monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2012/9/27/florida-institute-funds-miami-based-insero-health monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2012/2/2/insero-health-closes-initial-round-of-financing-and-signs-exclusive-licenses-with-harvard-and-yale monthly 0.5 2019-05-07 https://www.raphaelcapital.com/news/2010/8/19/emunamedica-licenses-technology-for-near-infrared-wound-monitor-from-drexel-university monthly 0.5 2019-05-07 https://www.raphaelcapital.com/home-nueva daily 1.0 2024-12-03 https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557240079593-2E4PB7GSFLRHX7UO2ZXY/GEORGIA-V-FC-1024x787.png Home https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557240194270-SNYPT8HBFOHC584SRZ06/yale-logo.png Home https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557239935202-P3WC7KBRNACMBIXVTHQK/1200px-Harvard_shield_wreath.svg.png Home https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557240387181-3VUE979G2MWTDSM1UWTI/drexel-university-logo02.png Home https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557163263945-2C7UWR72O5TG54Z88X2X/landscape-176602_1920.jpg Home https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1615897044564-ODCDV52SVP11EWBB5ZK8/barley-2117454_1920.jpg Home https://www.raphaelcapital.com/portfolio daily 0.75 2024-12-03 https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1615896697693-7CRUWJBXI5TLVXKYGER9/short+logo.png Portfolio https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557243512654-XG3H4CI5XZEOQ7L02RQI/significant+supplements.png Portfolio https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557243478980-AFEHUTAK29BBAKFCWVF3/emunamedica.png Portfolio https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557244468423-KSVSGD263SJMJ4ILAUFJ/F74C6A64-4335-4326-B1AE-386FB452CAD5.JPG Portfolio https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1557243494306-OH42PK5SOGE5VM9FWS0K/insero-logo.png Portfolio https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/b7eea8b4-5b2b-4984-8ccd-ee8c7e7f771b/Latent+Logo.png Portfolio - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.raphaelcapital.com/about-us daily 0.75 2024-12-03 https://images.squarespace-cdn.com/content/v1/5b195d857c93272edaa696cc/1615895875110-VBZ8IF8I04WEEGZ6T5QV/isolate-1209275_1920.jpg About Us “Here’s to the crazy ones — the misfits, the rebels, the troublemakers, the round pegs in the square holes. The ones who see things differently — they’re not fond of rules. You can quote them, disagree with them, glorify or vilify them, but the only thing you can’t do is ignore them because they change things. They push the human race forward, and while some may see them as the crazy ones, we see genius, because the ones who are crazy enough to think that they can change the world, are the ones who do.” - Steve Jobs